September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Choroidal metastases secondary to breast carcinoma: correlation with estrogen, progesterone and human epidermal growth factor-2 receptors
Author Affiliations & Notes
  • Raffaele Parrozzani
    Ocular Oncology and Toxicology Research Unit, G.B. Bietti Eye Foundation, Roma, Italy
  • Luisa Frizziero
    Department of Ophthalmology, University of Padova, Padova, Italy
  • giacomo miglionico
    Department of Ophthalmology, University of Padova, Padova, Italy
  • ilaria testi
    Department of Ophthalmology, University of Padova, Padova, Italy
  • pierdavide perrini
    Department of Ophthalmology, University of Padova, Padova, Italy
  • Edoardo Midena
    Department of Ophthalmology, University of Padova, Padova, Italy
    Ocular Oncology and Toxicology Research Unit, G.B. Bietti Eye Foundation, Roma, Italy
  • Footnotes
    Commercial Relationships   Raffaele Parrozzani, None; Luisa Frizziero, None; giacomo miglionico, None; ilaria testi, None; pierdavide perrini, None; Edoardo Midena, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5909. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Raffaele Parrozzani, Luisa Frizziero, giacomo miglionico, ilaria testi, pierdavide perrini, Edoardo Midena; Choroidal metastases secondary to breast carcinoma: correlation with estrogen, progesterone and human epidermal growth factor-2 receptors. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5909.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To analyze estrogen (ER), progesterone (PR), and human epidermal growth factor-2 (HER2) receptors expression in the primary tumor of patients affected by choroidal metastases of breast carcinoma (BC), and to compare these data with a control population composed by metastatic BC patients without choroidal involvement.

Methods : Fifteen consecutive patients affected by choroidal metastases by BC were consecutively included. ER, PR and HER2 positivity (+) of the primary tumor were defined following standard guidelines (any positive nuclear staining (ie, > 1%) for ER and PR; an immunohistochemistry score of 3+ or immunohistochemistry score of 2+ plus fluorescent in situ hybridization with amplification ratio > 2.0 for HER2). Forty consecutive patient affected by metastatic BC without choroidal involvement were also included as a control group.

Results : Patients affected by choroidal metastases by BC were characterized by ER+ in 15 cases (100%), PR+ in 13 cases (87%) and HER2+ in 3 cases (20%). Patient affected by metastatic BC without choroidal involvement were characterized by ER+ in 28 cases (70%), PR+ in 23 cases (58%) and HER2+ in 8 cases (19%). Patients affected by choroidal metastases by BC shows a statistically significant higher expression of ER (p=0.016) and PR (p=0.04) receptor in the primary tumor compared with non-choroidal metastatic BC. No difference for age, gender, race and histology of the primary tumor (ductal, lobular, others) were documented (P>0.05).

Conclusions : There is growing evidence about differences in metastatic homing among BC biologic subtypes based on receptors status. Choroidal metastases by BC appeared associated with ER and PR receptors expression in the primary tumor. Although the proven longer survival of ER+ and PR+ patients may have a role in the development of choroidal metastases by BC, ER and PR receptors expression may influence the choroidal metastatic tropism of this tumor.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×